Q: Are these capsules recommended for use without a doctors prescription
no refrigeration needed Retatrutide (triple-agonist GLP-1, GIP, glucagon) Status: Currently in Phase II/III trials Average weight loss: 17.524% in initial studies Notable facts: Promising triple-targeting mechanism for substantial weight reduction Mazdutide (IBI-362) Status: Approved in China as of June 2025
Testing looks at biomarkers associated with thyroid, heart, kidney, and liver health, along with your diabetes risk, and measures how these levels change as you lose weight
If you are looking into Mochi Health's GLP-1 program, the practical questions are how the service is organized, which medications tend to appear in a program like it, and what a prescription does and doesn't account for
Khan D, Sridhar A, Moffett CR
Yet, as with any supplement, outcomes are not guaranteed, and results vary